No Data
No Data
AbbVie Flags Hit to Q2 Adjusted Earnings From R&D Expenses, Revises 2024 Outlook
AbbVie (ABBV) expects its Q2 adjusted earnings to take a $0.52 per-share hit from acquired in-process research and development and milestones expense of $937 million on a pre-tax basis, according to a
AbbVie Q2 IPR&D Expenses to Lower EPS by $0.52
Express News | Abbvie Inc FY2024 Shr View $11.25 -- LSEG IBES Data
Express News | Abbvie -Q2 2024 Adjusted Diluted Earnings per Share Guidance Range, Including Impact of Q2 2024 Acquired Ipr&D, Milestones Expense $2.53 - $2.57
Express News | Abbvie: Earnings for Q2 of 2024 Expected to Include Acquired Ipr&D and Milestones Expense of $937 Mln on Pre-Tax Basis
Express News | Abbvie: 2024 Adj Diluted Eeps Guidance Range, Including Impact of Q2 2024 Acquired Ipr&D and Milestones Expense, Is $10.61 - $10.81